收费全文 | 458篇 |
免费 | 30篇 |
耳鼻咽喉 | 5篇 |
儿科学 | 2篇 |
妇产科学 | 1篇 |
基础医学 | 62篇 |
口腔科学 | 5篇 |
临床医学 | 40篇 |
内科学 | 77篇 |
皮肤病学 | 1篇 |
神经病学 | 103篇 |
特种医学 | 28篇 |
外科学 | 28篇 |
综合类 | 1篇 |
预防医学 | 10篇 |
眼科学 | 10篇 |
药学 | 45篇 |
肿瘤学 | 70篇 |
2023年 | 21篇 |
2022年 | 6篇 |
2021年 | 45篇 |
2020年 | 33篇 |
2019年 | 23篇 |
2018年 | 31篇 |
2017年 | 18篇 |
2016年 | 20篇 |
2015年 | 14篇 |
2014年 | 12篇 |
2013年 | 11篇 |
2012年 | 23篇 |
2011年 | 19篇 |
2010年 | 3篇 |
2009年 | 4篇 |
2008年 | 5篇 |
2007年 | 20篇 |
2006年 | 17篇 |
2005年 | 12篇 |
2004年 | 14篇 |
2003年 | 19篇 |
2002年 | 19篇 |
2001年 | 8篇 |
2000年 | 12篇 |
1999年 | 9篇 |
1998年 | 6篇 |
1997年 | 1篇 |
1996年 | 3篇 |
1995年 | 1篇 |
1994年 | 4篇 |
1993年 | 5篇 |
1992年 | 7篇 |
1991年 | 8篇 |
1990年 | 4篇 |
1989年 | 4篇 |
1988年 | 4篇 |
1987年 | 4篇 |
1986年 | 5篇 |
1985年 | 3篇 |
1984年 | 5篇 |
1983年 | 2篇 |
1980年 | 2篇 |
1979年 | 1篇 |
1971年 | 1篇 |
Methods: Individuals who visited the outpatient clinic or were admitted to the palliative care unit were eligible. Patients with a performance status of 4 and/or those unable to complete questionnaires were excluded. PA was evaluated using a bioanalyzer device. The correlation coefficient between PA and the variables of interest was analyzed.
Results: A total of 102 patients were analyzed. PA was weakly correlated with age (ρ = ?0.22), performance status (ρ = ?0.30), functional well-being (ρ?=?0.20), anorexia/cachexia subscale (ρ?=?0.22), and Functional Assessment of Anorexia/Cachexia Therapy trial outcome index (ρ?=?0.26). PA was also correlated with fluid retention (ρ = ?0.34) and albumin (ρ?=?0.32), C-reactive protein (ρ = ?0.31), and hemoglobin (ρ?=?0.41) levels. Sub-analysis stratified according to sex revealed that males demonstrated the same results; however, female sex demonstrated a correlation between PA and social well-being (ρ = ?0.43).
Conclusions: PA was correlated with physical condition, but not with psychological well-being. 相似文献
To compare the diagnostic performance of ring-type dedicated breast PET (dbPET), whole-body PET (WBPET), and DCE-MRI for predicting pathological complete response (pCR) after neoadjuvant chemotherapy (NAC).
MethodsThis prospective study included 29 women with histologically proven breast cancer on needle biopsy between July 2016 and July 2019 (age: mean 55 years; range 35–78). Patients underwent WBPET followed by ring-type dbPET and DCE-MRI pre- and post-NAC for preoperative evaluation. pCR was defined as an invasive tumor that disappeared in the breast. Standardized uptake values corrected for lean body mass (SULpeak) were calculated for dbPET and WBPET scans. Maximum tumor length was measured in DCE-MRI images.
Reduction rates were calculated for quantitative evaluation. Two radiologists independently evaluated the qualitative findings. Reduction rates and qualitative findings were compared between the pCR (n?=?7) and non-pCR (n?=?22) groups for each modality. Differences in quantitative and qualitative data between the two groups were analyzed statistically.
ResultsSignificant differences were observed in the reduction rates of dbPET and DCE-MRI (P?=?0.01 and 0.03, respectively) between the two groups. Univariate and multiple logistic regression analyses revealed that SULpeak reduction rates in WBPET and dbPET (P?=?0.02 and P?=?0.01, respectively) and in dbPET (odds ratio, 16.00; 95% CI 1.57–162.10; P?=?0.01) were significant indicators associated with pCR, respectively. No between-group differences were observed in qualitative findings in the three modalities.
ConclusionSULpeak reduction rate of dbPET?>?82% was an independent indicator associated with pCR after NAC in breast cancer.
相似文献The aim of this study was to evaluate the clinical significance of the on-treatment C-reactive protein (CRP) status during systemic treatment as the predictive marker for the response of subsequent nivolumab monotherapy in patients with refractory metastatic renal cell carcinoma (mRCC).
Patients and methodsA total of 73 mRCC patients treated with nivolumab were retrospectively reviewed. We evaluated the serum CRP levels before and after molecular-targeted treatments. Patients whose CRP did not exceed baseline value were defined as the CRP-control group and the others were defined as the CRP-progression group. The clinical impact of CRP-control on the efficacy of nivolumab was assessed.
ResultsTwenty-four patients (33%) were categorized into the CRP-control group. The CRP-control group patients (median PFS not reached) had significantly longer PFS than the CRP-progression group (median PFS 11.9 months, 95% confidence interval, CI 4.1–19.8, p?=?0.038). The CRP-control group had a tendency of longer OS from nivolumab initiation than the CRP-progression group (p?=?0.071). By multivariate analysis, the on-treatment CRP-control was the independent predictive factor for PFS (hazard ratio HR 0.37, 95% CI 0.14–0.99, p?=?0.047).
ConclusionThe on-treatment CRP-control could be the predictive factor for the efficacy of nivolumab in refractory mRCC patients.
相似文献